Valuation: Candel Therapeutics, Inc.

Market Cap 627M 557M 516M 470M 886M 59.48B 901M 6.21B 2.43B 31.04B 2.35B 2.3B 98.94B P/E 2026 *
-5.84x
P/E 2027 * -7.26x
Enterprise Value 627M 557M 516M 470M 886M 59.48B 901M 6.21B 2.43B 31.04B 2.35B 2.3B 98.94B EV / Sales 2026 *
-
EV / Sales 2027 * 14.1x
Free-Float
85.21%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Candel Therapeutics, Inc.

1 day-1.71%
1 week-18.10%
Current month-23.28%
1 month-28.55%
3 months-16.30%
6 months+10.94%
Current year+41.77%
1 week 7.98
Extreme 7.98
9.84
1 month 7.98
Extreme 7.98
12.01
Current year 4.44
Extreme 4.44
14
1 year 4.35
Extreme 4.35
14
3 years 0.66
Extreme 0.66
14.6
5 years 0.66
Extreme 0.66
14.6
10 years 0.66
Extreme 0.66
14.78
Manager TitleAgeSince
Chief Executive Officer 66 01/09/2020
Director of Finance/CFO 41 12/01/2024
Chief Tech/Sci/R&D Officer 57 12/09/2022
Director TitleAgeSince
Director/Board Member 80 01/09/2017
Director/Board Member 66 01/09/2020
Chairman 70 15/07/2021
Date Insider Type Main position Quantity % Market Cap. Importance
30/09/26 Free

Director

380 0.0005%
30/09/26 Free

Chairman

2,189 0.0029%
30/09/26 Free

Director

1,325 0.0017%
Change 5-day change 1-year change 3-year change Capi.($)
-1.77%-18.10%+44.58%+789.90% 627M
+1.52%-7.16%+51.66%+67.41% 65B
+1.03%+6.55%+10.60%+78.83% 51.2B
+0.38%-0.38%+0.05%+62.02% 51.19B
-0.87%+0.98%+24.87%+41.79% 43.93B
+0.13%+5.43%+15.96%+132.83% 41.96B
+1.28%-7.02%+233.90%+521.85% 38.14B
+2.16%+10.36%+18.92%+59.70% 33.24B
-0.90%-10.49%+37.09%+1.80% 25.2B
+1.60%+2.09%+27.81%+27.84% 22.5B
Average +0.46%-1.63%+46.54%+178.40% 37.3B
Weighted average by Cap. +0.72%+0.01%+45.05%+112.76%

Financials

2026 *2027 *
Net sales - 44.33M 39.4M 36.52M 33.23M 62.7M 4.21B 63.7M 439M 172M 2.2B 166M 163M 7B
Net income -101M -89.86M -83.29M -75.78M -143M -9.59B -145M -1B -393M -5.01B -379M -371M -15.96B -88.94M -79.06M -73.28M -66.67M -126M -8.44B -128M -881M -345M -4.4B -334M -327M -14.04B
Net Debt - -
Projected Income Statement - Annual - Candel Therapeutics, Inc.
Logo Candel Therapeutics, Inc.
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
Employees
55
Date Price Change Volume
19/10/26 $8.020 -2.08% 191,267
16/10/26 $8.190 -8.08% 1,513,092
15/10/26 $8.910 -1.76% 989,338
14/10/26 $9.070 -2.16% 989,443
13/10/26 $9.270 -5.21% 1,133,162
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Candel Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
8.190USD
Average target price
21.75USD
Spread / Average Target
+165.57%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Candel Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. CADL Stock